Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices.
暂无分享,去创建一个
Ian M Hastings | Nicholas J White | Shunmay Yeung | Wirichada Pongtavornpinyo | A. Mills | N. White | S. Yeung | I. Hastings | W. Pongtavornpinyo | Anne J Mills
[1] J. Aron. Malaria epidemiology and detectability. , 1982, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[2] B. Sharp,et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.
[3] J. Sachs,et al. The economic and social burden of malaria , 2002, Nature.
[4] A. Fleming,et al. Cost-effectiveness of malaria control in sub-Saharan Africa , 1999, The Lancet.
[5] A. Taylor-Robinson,et al. A model of development of acquired immunity to malaria in humans living under endemic conditions. , 2002, Medical hypotheses.
[6] S. McCombie. Treatment seeking for malaria: a review of recent research. , 1996, Social science & medicine.
[7] R. Snow,et al. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. , 2001, The American journal of tropical medicine and hygiene.
[8] I. Hastings. Modelling parasite drug resistance: lessons for management and control strategies , 2001, Tropical medicine & international health : TM & IH.
[9] J. Botella de Maglia,et al. [Prevention of malaria]. , 1999, Revista clinica espanola.
[10] C. Dolecek,et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial , 2004, The Lancet.
[11] Introduction. Antimalarial drug resistance: ramifications, explanations and challenges. , 2002, Microbes and infection.
[12] N. White,et al. The evolution of drug-resistant malaria: the role of drug elimination half-life. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[13] N. White. Why is it that antimalarial drug treatments do not always work? , 1998, Annals of tropical medicine and parasitology.
[14] M. Gatton,et al. Mutations in Cytochrome b Resulting in Atovaquone Resistance Are Associated with Loss of Fitness in Plasmodium falciparum , 2002, Antimicrobial Agents and Chemotherapy.
[15] R. Price,et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[16] B. Karoumi,et al. Vitamin therapy and prevention of neural tube defects , 2001 .
[17] Anne Mills,et al. The economic impact of malaria in Africa: a critical review of the evidence. , 2003, Health policy.
[18] R. Price,et al. Effects of artemisinin derivatives on malaria transmissibility , 1996, The Lancet.
[19] U. d’Alessandro,et al. Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.
[20] R. Snow,et al. The past, present and future of childhood malaria mortality in Africa. , 2001, Trends in parasitology.
[21] F Reed Johnson,et al. Modeling for health care and other policy decisions: uses, roles, and validity. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[22] O. Traoré,et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. , 2003, The American journal of tropical medicine and hygiene.
[23] N. White,et al. Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[24] K. Marsh. Malaria disaster in Africa , 1998, The Lancet.
[25] R. Baltussen,et al. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making. , 1999, PharmacoEconomics.
[26] R. Snow,et al. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. , 1999, Bulletin of the World Health Organization.
[27] M. Rauner,et al. Using Simulation for AIDS Policy Modeling: Benefits for HIV/AIDS Prevention Policy Makers in Vienna, Austria , 2002, Health care management science.
[28] A. Zwi,et al. Viewpoint: Management of malaria – working with the private sector , 1999, Tropical medicine & international health : TM & IH.
[29] K Dietz,et al. A malaria model tested in the African savannah. , 1974, Bulletin of the World Health Organization.
[30] A. Mills,et al. Economic analysis of malaria control in Sub-Saharan Africa , 2000 .
[31] E. Fèvre,et al. Malaria-treatment policies: when and how should they be changed? , 1999, Annals of tropical medicine and parasitology.
[32] P. Bloland,et al. Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub‐Saharan Africa , 1998, Tropical medicine & international health : TM & IH.
[33] B. Singer,et al. Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[34] N. White,et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. , 1994, The Journal of infectious diseases.
[35] G. Macdonald,et al. The analysis of infection rates in diseases in which superinfection occurs. , 1950, Tropical diseases bulletin.
[36] C. Ziba,et al. Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine‐pyremethamine and other antimalarial drugs in Malawian children , 2001, Tropical medicine & international health : TM & IH.
[37] W. Hawley,et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. , 1999, The American journal of tropical medicine and hygiene.
[38] P. Rees. Chloroquine resistant malaria. , 1984, East African medical journal.
[39] J. Trape. The public health impact of chloroquine resistance in Africa. , 2001, The American journal of tropical medicine and hygiene.
[40] C. Curtis,et al. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[41] J. Baird. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. , 1995, Parasitology today.
[42] Richard N. Price,et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.
[43] R. Snow,et al. Impact of Plasmodium falciparum malaria on performance and learning: review of the evidence. , 2001, The American journal of tropical medicine and hygiene.
[44] J. Breman,et al. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. , 2001, The American journal of tropical medicine and hygiene.
[45] J. Breman,et al. Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypoglycemia, and complications of pregnancy. , 2001, The American journal of tropical medicine and hygiene.
[46] P. Bloland,et al. Making malaria-treatment policy in the face of drug resistance. , 1999, Annals of tropical medicine and parasitology.
[47] B. Karoumi,et al. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience , 2001, Tropical medicine & international health : TM & IH.
[48] A. Brennan,et al. Modelling in health economic evaluation. What is its place? What is its value? , 2000, PharmacoEconomics.
[49] P. Newton,et al. Contribution of humoral immunity to the therapeutic response in falciparum malaria. , 2001, The American journal of tropical medicine and hygiene.
[50] M. Lwin,et al. Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar. , 1998, Bulletin of the World Health Organization.
[51] P. Olliaro,et al. Averting a malaria disaster , 1999, The Lancet.
[52] P. Bloland,et al. Combination therapy for malaria in Africa: hype or hope? , 2000, Bulletin of the World Health Organization.
[53] A. Buckling,et al. The effect of partial host immunity on the transmission of malaria parasites , 2001, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[54] C. Menéndez,et al. The burden of malaria in pregnancy in malaria-endemic areas. , 2001, The American journal of tropical medicine and hygiene.
[55] M. Enserink. Malaria Researchers Wait for Industry to Join Fight , 2000, Science.
[56] Joan L. Aron,et al. Mathematical modelling of immunity to malaria , 1988 .
[57] N. White. The assessment of antimalarial drug efficacy. , 2002, Trends in parasitology.